As shown in the CROWN trial, there is even a small population of NSCLC patients with ALK rearrangement in whom Crizotinib has sustained consistent response over five years [1], and Lorlatinib might represent an overtreatment. Here, ALK is linked to non-small cell lung carcinoma.